A model-based approach for the evaluation of once daily dosing of lamivudine in HIV-infected children

British Journal of Clinical Pharmacology

Volumn 77, Issue 5, 2014, Pages 852-860

  Piana, Chiara ^a   Zhao, Wei ^b,c   Adkison, Kimberly ^d   Burger, David ^e   Jacqz Aigrain, Evelyne ^b,c   Danhof, Meindert ^a   Della Pasqua, Oscar ^a,f  

^a LEIDEN UNIVERSITY   (Netherlands)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c INSERM   (France)

^d GLAXOSMITHKLINE   (United States)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

clinical trial simulations; compliance; dose rationale; lamivudine; model based drug development; paediatrics

Indexed keywords

LAMIVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AREA UNDER THE CURVE; ARTICLE; CHILD; CHILDHOOD DISEASE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIMULATION; STEADY STATE; BIOLOGICAL MODEL; BODY WEIGHT; DRUG ADMINISTRATION; HIV INFECTIONS; PRESCHOOL CHILD;

ANTI-HIV AGENTS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HUMANS; INFANT; LAMIVUDINE; MODELS, BIOLOGICAL;

EID: 84899045064     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12246     Document Type: Article

References (35)

1. Haberer J, Mellins C,. Pediatric adherence to HIV antiretroviral therapy. Curr HIV/AIDS Rep 2009; 6: 194-200.
2. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F,. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS (London, England) 2001; 15: 1369-1377.
3. Moyle G,. Once-daily therapy: less is more. Int J STD AIDS 2003; 14: (Suppl 1): 1-5.
4. Claxton AJ, Cramer J, Pierce C,. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310.
5. Manfredi R, Calza L,. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients. AIDS Patient Care STDS 2008; 22: 279-290.
6. Chokephaibulkit K, Cressey T, Capparelli E, Sirisanthana V, Muresan P, Hongsiriwon S, Ngampiyaskul C, Limwongse C, Wittawatmongko O, Aurpibul L, Kabat B, Toye M, Smith M, Eksaengsri A, McIntosh K, Yogev R,. Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/ nevirapine in HIV-infected children. Antivir Ther 2011; 16: 1287-1295.
7. Rosso R, Di Biagio A, Maggiolo F, Nulvesu L, Callegaro AP, Taramasso L, Bruzzone B, Viscoli C,. Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen. AIDS care 2012; 24: 54-58.
8. Taburet A-M, Paci-Bonaventure S, Peytavin G, Molina J-M,. Once-daily administration of antiretrovirals: pharmacokinetics of emerging therapies. Clin Pharmacokinet 2003; 42: 1179-1191.
9. Raboud J, Li M, Walmsley S, Cooper C, Blitz S, Bayoumi AM, Rourke S, Rueda S, Rachlis A, Mittmann N, Smieja M, Collins E, Loutfy MR,. Once daily dosing improves adherence to antiretroviral therapy. AIDS behav 2011; 15: 1397-1409.
10. Maitland D, Jackson A, Osorio J, Mandalia S, Gazzard BG, Moyle GJ,. Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy. HIV Med 2008; 9: 667-672.
11. Portsmouth SD, Osorio J, McCormick K, Gazzard BG, Moyle GJ,. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med 2005; 6: 185-190.
12. Bellanti F, Della Pasqua O,. Modelling and simulation as research tools in paediatric drug development. Eur J Clin Pharmacol 2011; 67: (Suppl 1): 75-86.
13. De Cock RFW, Piana C, Krekels EHJ, Danhof M, Allegaert K, Knibbe CAJ,. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol 2011; 67: (Suppl 1): 5-16.
14. Achenbach CJ, Scarsi KK, Murphy RL,. Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV. Adv ther 2010; 27: 1-16.
15. Moore KH, Barrett JE, Shaw S, Pakes GE, Churchus R, Kapoor A, Lloyd J, Barry MG, Back D,. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS (London, England) 1999; 13: 2239-2250.
16. DeJesus E, McCarty D, Farthing CF, Shortino DD, Grinsztejn B, Thomas DA, Schrader SR, Sension MG, Gough K, Madison SJ,. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin Infect Dis 2004; 39: 411-418.
17. Yuen GJ, Lou Y, Bumgarner NF, Bishop JP, Smith GA, Otto VR, Hoelscher DD,. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother 2004; 48: 176-182.
18. Boucher CA, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg MA, Cameron JM,. High-level resistance to (-) enantiomeric 2′-deoxy-3′- thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993; 37: 2231-2234.
19. Perry CM, Faulds D,. Lamivudine a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 1997; 53: 657-680.
20. Bergshoeff A, Burger D, Verweij C, Farrelly L, Flynn J, Le Prevost M, Walker S, Novelli V, Lyall H, Khoo S, Gibb D,. Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). Antivir ther 2005; 10: 239-246.
21. Paediatric European Network for Treatment of AIDS (PENTA). Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months. Antivir ther 2010; 15: 297-305.
22. The WHO Child Growth Standards. World Health Organization. 2013. Available at http://www.who.int/childgrowth/en/ (last accessed 20 October 2013).
23. World Health Organisation. Prequalification Programme. Summary of Product Characteristics of lamivudine. 2011. Available at http://apps.who.int/prequal/ whopar/whoparproducts/HA414Part4v1.pdf (last accessed 20 October 2013).
24. Piana C, Zhao W. Adkison K, Burger D, Jacqz-Aigrain E, Danhof M, Della Pasqua O,. Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children. Br J Clin Pharmacol 2014; 77: 861-872.
25. Yuen GJ, Esinhart JD, Rubin M,. Clinical Pharmacology Study Report. GlaxoSmithKline Document Number UCR/95/004. Study Protocol ID NUCA2002. A phase I/II study of 3TC (GR109714X) in children with HIV infection (Protocol No: NUCA2002). 1995. Available at http://www.gsk-clinicalstudyregister.com/result- detail.jsp?protocolId=NUCA2002&studyId=1DCBC204-B242-451B-A77D- 6F586F8FF319&compound=lamivudine (last accessed 20 October 2013).
26. Yuen GJ, Dawson D, Lou Y, Martinson M, Gillum BE, Stein DS,. GlaxoSmithKline Document Number RM2000/00258/00 Study Protocol ID EPV10001. An open-label, randomized, 2-way cross-over study to compare the steady-state pharmacokinetics of lamivudine and lamivudine triphosphate following lamivudine 300mg once daily versus EPIVIR 150 mg twice a day in healthy volunteers. Available at http://www.gsk-clinicalstudyregister.com/result-detail.jsp? protocolId=EPV10001&studyId=FA1B4634-22F2-4EE6-8C22- DF6951C705E9&compound=EPV10001&type=GSK+Study+ID&letterrange=All (last accessed 20 October 2013).
27. Bishai D, Colchero A, Durack DT,. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings. AIDS (London, England) 2007; 21: 1333-1340.
28. Burger DM, Verweel G, Rakhmanina N, Wissen CPWGM V-V, La Porte CJL, Bergshoeff AS, Lyall H, Hartwig NG, Green H, Soldin S, Gibb DM, de Groot R,. Age-dependent pharmacokinetics of lamivudine in HIV-infected children. Clin Pharmacol Ther 2007; 81: 517-520.
29. Kasirye P, Kendall L, Adkison KK, Tumusiime C, Ssenyonga M, Bakeera-Kitaka S, Nahirya-Ntege P, Mhute T, Kekitiinwa A, Snowden W, Burger DM, Gibb DM, Walker AS, ARROW Trial Team. Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. Clin Pharmacol Ther 2012; 91: 272-280.
30. Minuesa G, Volk C, Molina-Arcas M, Gorboulev V, Erkizia I, Arndt P, Clotet B, Pastor-Anglada M, Koepsell H, Martinez-Picado J,. Transport of lamivudine [(-)-beta-L-2′,3′-dideoxy-3′-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther 2009; 329: 252-261.
31. Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV,. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr 2006; 42: 441-449.
32. Roca B, Lapuebla C, Vidal-Tegedor B,. HAART with didanosine once versus twice daily: adherence and efficacy. Int J Infect Dis 2005; 9: 195-200.
33. Kazatchkine MD, Van PN, Costagliola D, Mohammed AS, Ledeine JM, Troccaz M, Belec L,. Didanosine dosed once daily is equivalent to twice daily dosing for patients on double or triple combination antiretroviral therapy. The AI454-147 Team. J Acquir Immune Defic Syndr 2000; 24: 418-424.
34. Monno L, Cargnel A, Soranzo ML, Chirianni A, Ferraro T, Di Stefano M, Angarano G,. Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team. Antivir ther 1999; 4: 195-202.
35. LePrevost M, Green H, Flynn J, Head S, Clapson M, Lyall H, Novelli V, Farrelly L, Walker AS, Burger DM, Gibb DM,. Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children. Pediatr Infect Dis J 2006; 25: 533-537.